[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Summit Therapeu ADR (SMMT)

Summit Therapeu ADR (SMMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,696,776
  • Shares Outstanding, K 776,163
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,080 M
  • EBIT $ -1,217 M
  • EBITDA $ -1,217 M
  • 60-Month Beta -1.32
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 21.13

Options Overview Details

View History
  • Implied Volatility 87.32% (-5.02%)
  • Historical Volatility 108.18%
  • IV Percentile 29%
  • IV Rank 23.71%
  • IV High 183.25% on 01/27/26
  • IV Low 57.51% on 01/21/26
  • Expected Move (DTE 1) 0.51 (3.45%)
  • Put/Call Vol Ratio 0.77
  • Today's Volume 3,375
  • Volume Avg (30-Day) 12,536
  • Put/Call OI Ratio 0.52
  • Today's Open Interest 179,899
  • Open Int (30-Day) 165,651
  • Expected Range 14.28 to 15.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.26
  • Number of Estimates 3
  • High Estimate $-0.26
  • Low Estimate $-0.26
  • Prior Year $-0.76
  • Growth Rate Est. (year over year) +65.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
14.17 +2.96%
on 06/02/26
19.42 -24.85%
on 05/11/26
-2.39 (-14.08%)
since 05/04/26
3-Month
14.17 +2.96%
on 06/02/26
29.23 -50.09%
on 04/21/26
-0.79 (-5.14%)
since 03/04/26
52-Week
13.83 +5.50%
on 02/05/26
30.98 -52.91%
on 08/05/25
-4.97 (-25.41%)
since 06/04/25

Most Recent Stories

More News
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China

Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen to Achieve a Statistically Significant...

SMMT : 14.49 (-3.85%)
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026

Promising Data Further Support Continued Expansion of Ivonescimab Clinical Development in mCRC Overall Study Population Achieved ORR of 70.8% and DCR of 100.0%; Responses...

SMMT : 14.49 (-3.85%)
Stocks Settle Higher on Iran Peace Hopes and Tech Strength

The S&P 500 Index ($SPX ) (SPY ) on Friday closed up +0.37%, the Dow Jones Industrial Average ($DOWI ) (DIA ) closed up +0.58%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.42%. June E-mini S&P...

AMAT : 500.36 (-0.08%)
INTU : 304.76 (-2.14%)
ADI : 427.98 (-2.21%)
DDOG : 245.90 (-1.77%)
MRK : 119.47 (+4.16%)
TXN : 305.58 (-0.98%)
$IUXX : 30,432.68 (-0.45%)
COIN : 163.24 (+0.01%)
ASML : 1,747.59 (+1.23%)
ZNU26 : 109-210 (+0.19%)
ESM26 : 7,597.25 (+0.34%)
QCOM : 240.13 (-3.60%)
Stocks Climb on US-Iran Peace Hopes and Strength in Chipmakers

The S&P 500 Index ($SPX ) (SPY ) today is up +0.50%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.63%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.73%. June E-mini S&P futures (ESM26...

AMAT : 500.36 (-0.08%)
INTU : 304.76 (-2.14%)
ADI : 427.98 (-2.21%)
DDOG : 245.90 (-1.77%)
MRK : 119.47 (+4.16%)
TXN : 305.58 (-0.98%)
$IUXX : 30,432.68 (-0.45%)
ASML : 1,747.59 (+1.23%)
ZNU26 : 109-210 (+0.19%)
ESM26 : 7,597.25 (+0.34%)
QCOM : 240.13 (-3.60%)
IBM : 302.40 (-1.06%)
Stocks Supported by US-Iran Peace Deal Optimism

The S&P 500 Index ($SPX ) (SPY ) today is up +0.54%, the Dow Jones Industrial Average ($DOWI ) (DIA ) is up +0.70%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.53%. June E-mini S&P futures (ESM26...

AMAT : 500.36 (-0.08%)
INTU : 304.76 (-2.14%)
ADI : 427.98 (-2.21%)
DDOG : 245.90 (-1.77%)
MRK : 119.47 (+4.16%)
TXN : 305.58 (-0.98%)
$IUXX : 30,432.68 (-0.45%)
ASML : 1,747.59 (+1.23%)
ZNU26 : 109-210 (+0.19%)
MSFT : 426.58 (-0.18%)
ESM26 : 7,597.25 (+0.34%)
QCOM : 240.13 (-3.60%)
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026

Overall Survival Data to be Featured at ASCO 2026 Plenary Session as Late-Breaking Abstract from HARMONi-6, a Phase III Study in 1L Squamous NSCLC in China Update Conference...

SMMT : 14.49 (-3.85%)
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026

Three Poster Presentations Will Feature Updated Ivonescimab Data, including Intracranial Anti-Tumor Activity from the Global HARMONi Phase III Study

SMMT : 14.49 (-3.85%)
Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it will participate in three upcoming investor conferences during March of this year. Members...

SMMT : 14.49 (-3.85%)
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025

HARMONi-3 Squamous Cohort of Global Phase III 1L NSCLC Study: Interim PFS Analysis Planned in Q2 2026; Final PFS and Interim OS Data Planned in Second Half of 2026 ...

SMMT : 14.49 (-3.85%)
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026

Conference Call to be Held at 4:30pm ET

SMMT : 14.49 (-3.85%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Summit Therapeutics PLC is engaged in the discovery and development of drug to treat the fatal muscle wasting disease Duchenne Muscular Dystrophy and infections caused by the bacteria C. difficile. Summit Therapeutics PLC is headquartered in Abingdon, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 16.19
2nd Resistance Point 15.65
1st Resistance Point 15.36
Last Price 14.49
1st Support Level 14.53
2nd Support Level 13.98
3rd Support Level 13.69

See More

52-Week High 30.98
Fibonacci 61.8% 24.43
Fibonacci 50% 22.40
Fibonacci 38.2% 20.38
Last Price 14.49
52-Week Low 13.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.